Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
Clinical trial NCT03444506 · COMPLETED
Trial details
- NCT number
- NCT03444506
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-01-27
- Primary completion
- 2014-02-28
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.